-

07:43:22 AM

INAB Stock News

INAB - IN8bio Inc

03/30/23 4:15 PM

Nasdaq : INAB

earningslow float

IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated clinical data to be reported at the EBMT Annual Meeting in April 2023 INB-200 continued to show

RHEA-AI

neutral

03/16/23 8:00 AM

Nasdaq : INAB

conferencesclinical triallow float

IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023

INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. Data supports the potential for this next-generation CAR-T technology in previously “undruggable” solid- and liquid-tumor targets. NEW

RHEA-AI

neutral

03/01/23 8:00 AM

Nasdaq : INAB

conferenceslow float

IN8bio to Present at the Cowen 43rd Annual Healthcare Conference

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the Cowen 43 rd Annual

RHEA-AI

neutral

02/23/23 7:00 AM

Nasdaq : INAB

clinical triallow float

IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue

Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling gamma-delta CAR-T platform (nsCAR) utilizing the validated target of CD19 as proof-of-concept.

RHEA-AI

neutral

02/21/23 7:00 AM

Nasdaq : INAB

conferenceslow float

IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy

RHEA-AI

neutral

01/17/23 7:00 AM

Nasdaq : INAB

conferenceslow float

IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the B. Riley Securities’ 3 rd

RHEA-AI

neutral

01/05/23 7:00 AM

Nasdaq : INAB

low float

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM).

RHEA-AI

neutral

01/03/23 7:00 AM

Nasdaq : INAB

conferenceslow float

IN8bio to Present at Biotech Showcase 2023 in San Francisco

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today

RHEA-AI

neutral

12/12/22 7:00 AM

Nasdaq : INAB

clinical triallow float

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months) INB-100 continues to demonstrate a manageable safety profile with no dose-limiting toxicities (DLTs) observed to

RHEA-AI

neutral

12/08/22 7:00 AM

Nasdaq : INAB

clinical triallow float

IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being presented at the American Society of Hematology (ASH) on Monday, December 12th at 8:30 a.m. ET NEW YORK,

RHEA-AI

neutral

1 2 3 4 5 6 Next